A new genomic test could help breast cancer patients avoid chemotherapy by analyzing tumor gene activity to assess recurrence risk. The test helps doctors identify low-risk patients who may safely opt for hormone therapy instead and side effects while maintaining similar survival outcomes in early-stage cases with personalized precision.